Esprit Pharma, Inc. today announced that it has elected Robert E. Baldini to its Board of Directors.
Mr. Baldini has over fifty years of pharmaceutical experience with major and specialty pharmaceutical companies such as Pfizer, Geigy, Ciba-Geigy, Schering Plough, Key Pharmaceuticals and most recently Kos Pharmaceuticals. In addition to holding several senior level positions in sales, marketing and management, Mr. Baldini served as President of Key Pharmaceuticals and Vice Chairman of Kos Pharmaceuticals. He was personally involved in introducing over twenty-seven major pharmaceutical products into the marketplace.
“I am very pleased to welcome Bob Baldini to the Esprit Board,” said Mr. John T. Spitznagel, Chairman and CEO of Esprit Pharma. “Bob brings invaluable experience in pharmaceuticals and will be a great asset to Esprit as it continues to grow,” concluded Mr. Spitznagel.
Commenting on today’s announcement, Mr. Baldini noted, “I am excited to be joining the Board of a company which I believe will have a significant impact in the specialty pharma arena. Esprit is a young, vibrant company with excellent growth potential and I look forward to utilizing my experience in contributing to that growth.”
Currently, Mr. Baldini consults with several companies including Oikos Ventures and serves as Director of Arisaph Pharmaceuticals as well as DermWorx. He also served as a Director for Ascent Pediatrics.
Mr. Baldini received his BS from Seton Hall University and MBA from NYU. He currently serves on the Board of Regents at Seton Hall University.
About Esprit Pharma
Esprit Pharma is a niche oriented, forward thinking pharmaceutical company committed to improving patient outcomes and well-being within the urology and women’s health care fields. Led by a highly experienced management team, Esprit focuses on serving the unique needs of these physician specialties by selectively acquiring and maximizing the potential of approved and late-stage development medicines and providing support through internal expertise and a dedication to medical education. Esprit is a privately held company with investment support from several leading healthcare venture capital and private equity firms. For additional information visit the Company’s Internet site at www.espritpharma.com.
Comments